From the Research
The Inspire sleep device is indicated for adults with moderate to severe obstructive sleep apnea (OSA) who have failed or cannot tolerate continuous positive airway pressure (CPAP) therapy, with specific indications including an apnea-hypopnea index (AHI) between 15 and 65 events per hour, a body mass index (BMI) less than 35 kg/m², and absence of complete concentric collapse at the level of the soft palate as determined by drug-induced sleep endoscopy, as supported by the most recent study 1.
Key Indications
- Adults with moderate to severe OSA
- Failed or cannot tolerate CPAP therapy
- AHI between 15 and 65 events per hour
- BMI less than 35 kg/m²
- Absence of complete concentric collapse at the level of the soft palate
Device Mechanism
The Inspire system consists of three components: a small generator implanted in the upper chest, a breathing sensor lead placed between the ribs, and a stimulation lead connected to the hypoglossal nerve. Patients control the device with a remote control, turning it on before sleep and off upon waking. This therapy is particularly valuable for patients who cannot use CPAP due to mask discomfort, claustrophobia, or persistent air leaks, offering them an effective alternative to manage their sleep apnea.
Quality of Life Impact
The Inspire device has been shown to have a positive impact on quality of life, with improvements in usual activities and anxiety/depression, as demonstrated in a study published in 2022 1. The study found that patients with moderate to severe OSA who received the Inspire device had significant improvements in their quality of life, with a positive impact on their overall well-being.
Comparison to Other Treatments
While other treatments, such as oral appliance therapy and combination therapy with CPAP and mandibular advancement devices, have been shown to be effective in managing OSA, the Inspire device offers a unique alternative for patients who cannot tolerate CPAP therapy, as supported by studies 2, 3, 4. Additionally, the device has been shown to be effective in reducing apnea events and improving sleep quality, making it a valuable treatment option for patients with moderate to severe OSA.